EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/78721
For patients starting or changing PGA therapy, consider… 91 A drop with low dropout Prescribe LUMIGAN® 0.01% effi cacy with low discontinuation 2 ® Important Safety Information Warnings and Precautions: Pigmentation: Bimatoprost ophthalmic solution has been reported to cause changes to pigmented tissues: most frequently, increased pigmentation of the iris, eyelid, and eyelashes. Increases are expected as long as bimatoprost is administered. Iris color change may not be noticeable for several months to years. After discontinuation of bimatoprost, iris pigmentation is likely to be permanent, while eyelid and eyelash changes have been reported to be reversible in some patients. Patients should be informed of the possibility of increased pigmentation. The long-term effects of increased pigmentation are not known. Intraocular Inflammation: LUMIGAN 0.01% and 0.03% should be used ® with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated. Macular Edema: Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution. LUMIGAN ® 0.01% and 0.03% should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. Adverse Reactions: In clinical studies with bimatoprost ophthalmic solutions (0.01% or 0.03%), the most common adverse event was conjunctival hyperemia (range 25%-45%). Approximately 0.5% to 3% of patients discontinued therapy due to conjunctival hyperemia with 0.01% or 0.03% bimatoprost ophthalmic solutions. Other common events (> 10%) included growth of eyelashes and ocular pruritus. Please see brief prescribing information on adjacent page. % Commercial and Part D member lives covered as of 03/29/11 1 Indication: LUMIGAN 0.01% and 0.03% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. 1. Medimedia Formulary Compass. March 2011. 2. LUMIGAN ® Visit us at www.lumigan.com ©2011 Allergan, Inc., Irvine, CA 92612 ® APC53EG11 111197 marks owned by Allergan, Inc. 0.01% and 0.03% Prescribing Information.